Dr. Baretti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Education & Training
University of Pisa Faculty of MedicineClass of 2012
Certifications & Licensure
MD State Medical License 2021 - 2026
Publications & Presentations
PubMed
- Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma.Daniel J Zabransky, Emma Kartalia, Jae W Lee, James M Leatherman, Soren Charmsaz
Hepatology. 2024-12-03 - 1 citationsEntinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.Marina Baretti, Ludmila Danilova, Jennifer N Durham, Courtney B Betts, Leslie Cope
Nature Communications. 2024-11-12 - 1 citationsPathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.Antonio D'Alessio, Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley
The Lancet. Oncology. 2024-11-01
Press Mentions
Entinostat + Nivolumab Yields Durable Results in Some Pancreatic Cancer PatientsNovember 22nd, 2024- Drug Combination Boosts Immune Response in Resistant Pancreatic CancersNovember 15th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
